NASDAQ:ZFGN

Zafgen Stock Forecast, Price & News

$19.61

+0.01 (+0.05 %)

(As of 01/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$18.56

Now: $19.61▼

$20.22

50-Day Range

$0.99

MA: $18.73▼

$25.06

52-Week Range

$0.62

Now: $19.61▼

$2.76

Volume34,430 shs

Average Volume360,199 shs

Market Capitalization$734.79 million

P/E RatioN/A

Dividend YieldN/A

Beta0.27

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

MarketRank^™

Overall MarketRank^™

0.85 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Zafgen.

2.6 Community Rank

Outperform Votes
Zafgen has received 345 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zafgen has received 316 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zafgen has received 52.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote “Outperform” if you believe ZFGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zafgen does not currently pay a dividend.
Dividend Growth
Zafgen does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zafgen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.20% of the stock of Zafgen is held by insiders.
Percentage Held by Institutions
70.43% of the stock of Zafgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Zafgen is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zafgen is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zafgen has a P/B Ratio of 14.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZFGN

Previous Symbol

CUSIPN/A

CIK1374690

Webwww.zafgen.com

Phone617-622-4003

Employees38

Debt

Debt-to-Equity Ratio0.26

Current Ratio6.56

Quick Ratio6.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.35 per share

Price / Book14.53

Profitability

EPS (Most Recent Fiscal Year)($1.07)

Net Income$-45,410,000.00

Net MarginsN/A

Return on Equity-51.34%

Return on Assets-34.55%

Miscellaneous

Outstanding Shares37,470,000

Market Cap$734.79 million

Next Earnings DateN/A

OptionableOptionable

$19.61

+0.01 (+0.05 %)

(As of 01/19/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 2,206.8% and is now trading at $19.61.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Zafgen?

Wall Street analysts have given Zafgen a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zafgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting analysts' consensus estimates of ($0.19).
View Zafgen's earnings history.

Who are some of Zafgen's key competitors?

Some companies that are related to Zafgen include Axsome Therapeutics (AXSM), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Deciphera Pharmaceuticals (DCPH), Intra-Cellular Therapies (ITCI), Karuna Therapeutics (KRTX), Cryoport (CYRX), Amarin (AMRN), Zymeworks (ZYME), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), Seres Therapeutics (MCRB), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY) and Praxis Precision Medicines (PRAX).
View all of ZFGN's competitors.

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX), CA (CA), Endologix (ELGX), Energy Transfer (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:

Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $19.61.

How big of a company is Zafgen?

Zafgen has a market capitalization of $734.79 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

What is Zafgen's official website?

The official website for Zafgen is www.zafgen.com.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here